# US biotechnology sector IPO activity

> Live situation record from CLSTR: https://clstr.news/situations/us-biotechnology-sector-ipo-activity
> Updated: 2026-10-26T06:07:31.000Z. Sources: 3. Developments: 2.

Biotechnology companies have begun pursuing initial public offerings (IPOs) to fund clinical development despite market uncertainty. 

City Therapeutics, a Massachusetts-based firm specializing in RNA-based rare disease drugs, has targeted a valuation of up to $956.3 million to fund clinical trials for its lead candidate, CITY-FXI, and to advance its RNA interference platform. 

Lycia Therapeutics, which utilizes a Lysosomal Targeting Chimera (LYTAC) platform to develop treatments for allergies and autoimmune diseases, successfully completed its NASDAQ debut. The company raised $317.5 million through the issuance of 17.64 million new shares priced at $18.00 each. On its first day of trading, the stock closed at $30.00, a 67 percent increase from the IPO price.

## Timeline

### 2026-10-26: Lycia Therapeutics sees successful NASDAQ debut

Lycia Therapeutics shares surged 67 percent to close at $30.00 on their first day of trading on the NASDAQ following a $317.5 million IPO.

3 sources. https://clstr.news/cluster/lycia-therapeutics-sees-successful-nasdaq-debut

### 2026-10-07: Biotech firms City Therapeutics and Lycia Therapeutics pursue US IPOs

Biotech firms City Therapeutics and Lycia Therapeutics are pursuing US IPOs to fund clinical development of RNA-based rare disease treatments and food allergy therapies.

2 sources. https://clstr.news/cluster/biotech-firms-city-therapeutics-and-lycia-therapeutics-pursue-us-ipos

---
Cite as: US biotechnology sector IPO activity. CLSTR, https://clstr.news/situations/us-biotechnology-sector-ipo-activity